PAVmed (PAVM) Registration Filing summary

Company overview and business model

• Operates as a multi-product life sciences company advancing a pipeline of innovative healthcare technologies through distinct subsidiaries for each financed asset.

• Focuses on commercial expansion of EsoGuard (Lucid Diagnostics) and the Veris Cancer Care Platform (Veris Health), targeting large unmet medical needs.

• Employs a flexible capital structure, raising funds at the parent or subsidiary level as market conditions dictate.

• Recent developments include a MolDx submission for Medicare coverage of EsoGuard, publication of clinical validation data, and a Notice of Allowance for a key patent.

• Veris Health received a $1.8 million NIH grant to optimize its platform for underserved cancer patients.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is $12,193,857 as of December 3, 2024.

• Sold $1,882,380 of securities in the prior 12 months under Form S-3.

• Lucid Diagnostics raised $22 million in convertible notes in November 2024, with $18.4 million net proceeds after repayment of prior notes.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes.

• Specific allocations for each offering will be detailed in the relevant prospectus supplement.

• Pending use, proceeds will be invested in short-term, interest-bearing, investment-grade marketable securities or money market obligations.